US Patent 7732613 Met kinase inhibitors
Patent 7732613 was granted and assigned to Bristol-Myers Squibb on June, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+135 characters)
Article
Patent abstract
The present invention is directed to compounds that are useful for treating cancer having one of the following Formulas:
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07732613 Met kinase inhibitors US Patent 7732613 Met kinase inhibitors
Infobox
Patent Number
0773261300
Patent Number
773261300
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
077326130
Date of Patent
June 8, 2010
0Patent Application Number
115205200
Date Filed
September 13, 2006
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
077326130
Date of Patent
June 8, 2010
0Patent Application Number
115205200
Date Filed
September 13, 2006
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07732613 Met kinase inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07732613
Date of patent
June 8, 2010
Patent application number
11520520
Date Filed
September 13, 2006
Patent primary examiner
Find more entities like US Patent 7732613 Met kinase inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
